The impact of bulky mass on treatment response and overall survival in patients with diffuse large B-cell lymphoma in rituximab era Rituksimab çağında diffüz büyük b hücreli lenfoma hastalarında bulky kitlenin tedavi yanıtı ve genel sağkalıma etkisi
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.28, sa.4, ss.248-253, 2018 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 28 Sayı: 4
- Basım Tarihi: 2018
- Doi Numarası: 10.4999/uhod.183058
- Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.248-253
- Anahtar Kelimeler: Diffuse large B cell lymphoma, Bulky mass, Rituximab
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
We aim to evaluate the prognostic value of the presence of bulky mass at the time of diagnosis in patients with diffuse large B cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The data of 86 patients were analyzed retrospectively. The patients were divided into 2 groups according to the presence of bulky mass. The impact of bulky disease on treatment response and overall survival (OS) in patients receiving R-CHOP therapy was assessed. Twenty five (28.7%) patients had bulky disease. Sixteen of 25 patients (64%) with bulky mass achieved CR, whereas 53 of 59 patients (90%) without bulky mass achieved CR (p= 0.015). Within a median 17 months (range, 3-86) of follow up period, 16 (18.6%) of the patients died. Among them, 9 patients had bulky disease. The probability of OS at the end of follow-up time was 54% in patients with bulky disease and 87% in patients without bulky disease (p= 0.007). Cox regression analysis showed that the presence of bulky disease had a negative impact on OS (p= 0.012); however this effect was not independent of IPI (p= 0.078). We found that the presence of bulky mass is a poor prognostic factor in DLBCL patients treated with R-CHOP regimen.